{"analyses":[{"ciLowerLimit":"30.8","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"51.4","groupDescription":"The a priori plan was to compare MRD positivity rate with that on a prior study, AALL0031 (n=72 Cohorts 1-5 of AALL0031 with 71% MRD positive). Out of 59 patients with end-Induction MRD on AALL0622, 40.7% were MRD positive. Per protocol, rates will be compared with a 2 sample Z-test of proportions, 1-sided test, alpha=5%.","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.001","paramType":"Percentage","paramValue":"40.7","statisticalComment":"Chi-squared test equivalent to Z-test of proportions.","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.8","upperLimit":"51.4","value":"40.7"},{"groupId":"OG001","lowerLimit":"19.7","upperLimit":"40.9","value":"29.2"},{"groupId":"OG002","lowerLimit":"73.1","upperLimit":"100.0","value":"100.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"description":"Percent of patients MRD Positive (MRD \\> 0.01%) at End of Induction.","dispersionType":"90% Confidence Interval","groups":[{"description":"See Detailed Description\n\nAsparaginase: Given IT\n\nCyclophosphamide: Given IV\n\nCytarabine: Given IT or IV\n\nDasatinib: Given PO\n\nDaunorubicin Hydrochloride: Given IV\n\nDexamethasone: Given IV or PO\n\nEtoposide: Given IV\n\nFilgrastim: Given IV or SC\n\nHydrocortisone Sodium Succinate: Given IT\n\nIfosfamide: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLeucovorin Calcium: Given IV or PO\n\nMercaptopurine: Given PO\n\nMethotrexate: Given IT, PO, or IV\n\nMethylprednisolone: Given IV\n\nPegaspargase: Given IM\n\nPrednisone: Given PO or IV\n\nRadiation Therapy: Some patients undergo cranial RT\n\nVincristine Sulfate: Given IV","id":"OG000","title":"Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)"},{"description":"Based on Minimal Residual Disease, less than 1%.","id":"OG001","title":"Standard-risk"},{"description":"Based on Minimal Residual Disease, great than or equal to 1%.","id":"OG002","title":"High-risk"}],"paramType":"NUMBER","populationDescription":"Patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).","reportingStatus":"POSTED","timeFrame":"At the end of induction therapy (at 5 weeks)","title":"Contribution of Dasatinib on Minimal Residual Disease (MRD) After Induction Therapy","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}